PHAR — Pharming Group N.V. Stock Price, Chart & AI Report

Positive May 7, 2026 • 05:00 UTC GlobeNewswire Inc. • Na

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

Pharming Group reported Q1 2026 revenues of US$72.4 million (8% decrease YoY), with RUCONEST® declining 15% due to anticipated inventory drawdowns and market exit, while Joenja® grew 34% YoY. The company resubmitted pediatric sNDA to FDA for Joenja® and received positive CHMP opinion for European approval. Pharming maintained 2026 revenue guidance of US$405-425 million and generated positive operating cash flow of US$2.0 million.

PHAR Q1 2026 financial results RUCONEST® revenue decline Joenja® growth pediatric label expansion FDA resubmission CHMP positive opinion Japan approval

Sentiment note

Despite Q1 revenue decline, the company demonstrated strong Joenja® growth (34% YoY), achieved regulatory milestones (Japan approval, positive CHMP opinion, FDA resubmission), maintained full-year guidance, and achieved positive operating cash flow. Pipeline advancement and commercial execution support long-term growth prospects.

Neutral Apr 23, 2026 • 06:00 UTC GlobeNewswire Inc. • Na

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Pharming Group N.V. will report its preliminary Q1 2026 financial results and provide a business update on May 7, 2026, with a conference call and webcast for analysts and investors. The company will also hold its 2026 Annual General Meeting of Shareholders on May 28, 2026.

PHAR Q1 2026 results conference call webcast Annual General Meeting financial results investor update

Sentiment note

The article is a routine announcement of scheduled financial results reporting and shareholder meetings. It contains no information about business performance, product developments, or market conditions that would indicate positive or negative sentiment. It is purely procedural in nature.

Positive Apr 7, 2026 • 06:00 UTC GlobeNewswire Inc. • Na

Pharming Group to participate in April investor conferences

Pharming Group N.V. announced its participation in investor conferences in April 2026, including the Needham Virtual Healthcare Conference and Van Lanschot Kempen Life Sciences Conference. The company also announced a positive CHMP (Committee for Medicinal Products for Human Use) opinion for Joenja® (leniolisib) for treating APDS in adult and pediatric patients 12 years and older, and filed its 2025 Annual Report on Form 20-F.

PHAR Pharming Group Joenja leniolisib APDS CHMP opinion biopharmaceutical rare diseases

Sentiment note

The company received a positive CHMP opinion for its drug Joenja®, which is a significant regulatory milestone that could lead to market approval in Europe. This represents progress in the company's pipeline and validates its therapeutic approach for treating APDS.

Positive Mar 24, 2026 • 06:00 UTC GlobeNewswire Inc. • Pharming Group N.V.

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

Pharming Group announced that Japan's Ministry of Health, Labour and Welfare has approved Joenja® (leniolisib) for treating APDS in patients aged 4 years and older. This marks the first approved treatment for APDS in Japan and the first global approval for children aged 4-11 with the disease. The approval was based on positive Phase III clinical trial data showing significant improvements in lymphadenopathy reduction and naïve B cell percentage.

PHAR APDS approval leniolisib Japan regulatory approval rare immunodeficiency pediatric treatment PI3K delta inhibitor orphan drug

Sentiment note

Approval of Joenja in Japan represents a significant regulatory milestone, expanding market access and commercial opportunities. The approval for the youngest age group (4-11 years) globally is a competitive advantage. The company also reported strong 2025 financial results with revenue growth, profitability, and positive cash flow, indicating solid business performance.

Negative Feb 24, 2026 • 21:50 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

Pomerantz Law Firm is investigating Pharming Group N.V. for potential securities fraud following the FDA's issuance of a Complete Response Letter rejecting the company's supplemental application for Joenja® (leniolisib) for pediatric patients. The FDA cited concerns about drug underexposure in lower weight patients and analytical method issues. The news triggered a 17.07% stock price decline on February 2, 2026.

PHAR securities fraud FDA rejection Complete Response Letter Joenja leniolisib APDS class action lawsuit

Sentiment note

The company received an FDA Complete Response Letter rejecting its drug application for pediatric use, citing safety and analytical concerns. This regulatory setback resulted in a significant 17.07% stock price decline and triggered a securities fraud investigation, indicating substantial negative impact on investor confidence and company prospects.

Negative Feb 1, 2026 • 20:17 UTC GlobeNewswire Inc. • Pharming Group

Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS

Pharming Group received a Complete Response Letter from the FDA for its supplemental application to expand Joenja® (leniolisib) to children aged 4-11 with APDS. The FDA requested additional pediatric pharmacokinetic data to address concerns about potential underexposure in lower weight patients and clarification on analytical batch testing methods. Pharming plans to work with the FDA to address these issues and request a Type A meeting for resubmission. The existing approval for patients 12 years and older remains unaffected.

PHAR Complete Response Letter FDA Joenja leniolisib APDS pediatric pharmacokinetic

Sentiment note

The company received a Complete Response Letter, which is a regulatory setback requiring additional data submission and delaying approval for the pediatric indication. While management expressed confidence in addressing the issues, this represents a near-term disappointment and extends the timeline for market expansion of Joenja in younger children.

Positive Sep 2, 2025 • 05:00 UTC GlobeNewswire Inc. • Pharming Group N.V.

Pharming Group appoints Kenneth Lynard as Chief Financial Officer

Pharming Group N.V. announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. Lynard brings over 20 years of global finance leadership experience in life sciences, previously serving as CFO at Schoeller Allibert, Zentiva, and holding senior roles at Gilead Sciences.

GILD PHAR CFO appointment life sciences pharmaceutical leadership finance

Sentiment note

Company is strengthening financial leadership, demonstrating growth strategy and attracting experienced executive talent

Positive Feb 28, 2025 • 07:00 UTC GlobeNewswire Inc. • N/A

Pharming Group to participate in March investor conference

Pharming Group N.V., a global biopharmaceutical company, announces that its management team will participate in the 37th Annual Roth Conference in March 2025, where they will hold a fireside chat and be available for one-on-one meetings.

PHAR Pharming Group N.V. 37th Annual Roth Conference

Sentiment note

The article announces Pharming's participation in an investor conference, which suggests the company is actively engaging with the investment community and providing updates on its business activities, which is generally seen as a positive sign.

Positive Feb 10, 2025 • 07:00 UTC GlobeNewswire Inc. • N/A

Pharming Group to participate in February investor conference

Pharming Group N.V., a global biopharmaceutical company, announces that its management team will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025.

PHAR Pharming Group N.V. Oppenheimer 35th Annual Healthcare Life Sciences Conference

Sentiment note

The article announces that Pharming's management team will be presenting at an investor conference, which suggests the company is actively engaging with the investment community and is likely in a good position to showcase its business and pipeline.

Positive Dec 15, 2024 • 18:45 UTC GlobeNewswire Inc. • N/A

Pharming announces public cash offer to the shareholders of Abliva AB

Pharming Group N.V. announced a recommended public cash offer to acquire all outstanding shares of Abliva AB, a biotechnology company focused on developing treatments for mitochondrial diseases. Abliva's lead product, KL1333, is currently in a pivotal clinical trial and has shown positive results in a proof-of-concept study.

PHAR Pharming Abliva KL1333 mitochondrial disease acquisition

Sentiment note

Pharming is acquiring Abliva to strengthen its late-stage pipeline with a potential first-in-disease asset, KL1333, which is in a pivotal clinical trial for the treatment of mitochondrial diseases. This acquisition aligns with Pharming's vision to become a leading global rare disease company.

Positive Nov 5, 2024 • 07:00 UTC GlobeNewswire Inc. • N/A

Pharming Group to participate in November investor conference

Pharming Group N.V., a global biopharmaceutical company, announces that its CEO will present at the Jefferies London Healthcare Conference 2024 on November 20, 2024.

PHAR Pharming Group N.V. Jefferies London Healthcare Conference 2024

Sentiment note

The article announces that Pharming's CEO will present at an investor conference, which suggests the company is actively engaging with investors and showcasing its business developments.

Unknown Apr 22, 2024 • 09:29 UTC Zacks Investment Research • Zacks Equity Research

Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?

Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

PHAR URGN